CHRW
53
2
INTU
54
2
NWL
48
4
ABBV
40
5
UAL
73
3
DUK
49
4
MSI
52
3
MTB
38
4
DTE
49
16
CI
35
2
L
54
5
DHI
36
3
JWN
72
9
SCHW
40
3
SO
48
6
PEG
53
7
ADI
54
4
MU
42
14
UA
48
6
ES
12
3
CHRW
53
2
INTU
54
2
NWL
48
4
ABBV
40
5
UAL
73
3
DUK
49
4
MSI
52
3
MTB
38
4
DTE
49
16
CI
35
2
L
54
5
DHI
36
3
JWN
72
9
SCHW
40
3
SO
48
6
PEG
53
7
ADI
54
4
MU
42
14
UA
48
6
ES
12
3
Financhill
Back

Intellia Therapeutics 10K Form

Sell
5

NTLA
Intellia Therapeutics

Last Price:
$12.20
Seasonality Move:
-3.92%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive NTLA News And Ratings

See the #1 stock for the next 7 days that we like better than NTLA

NTLA Financial Statistics

Sales & Book Value

Annual Sales: $36.3M
Cash Flow: $-86.1M
Price / Cash Flow: 0
Annual Sales: $9.46
Price / Book: 1.29

Profitability

EPS (TTM): -5.44000
Net Income (TTM): $-522.3M
Gross Margin: --
Return on Equity: -51.64%
Return on Assets: -42.33%

Intellia Therapeutics Earnings Forecast

Key Intellia Therapeutics Financial Ratios

  • The Research & Development expenses have been 1,199.36% of Revenue.
  • The Net Earning history of NTLA is -1,326.51% of Total Revenues.
  • Per Share Earnings over the last 9 years have been positive in 1 years.

Intellia Therapeutics Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: NTLA
CUSIP: 45826J
Website: intelliatx.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 6.73
Quick Ratio: 6.31

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

NTLA Technical Analysis vs Fundamental Analysis

Sell
5
Intellia Therapeutics (NTLA) is a Sell

Is Intellia Therapeutics a Buy or a Sell?